ERYTECH PHARMA (ERYP.PA)
FR0011471135 - Common Stock
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 38.79M | 33.70M | 44.45M | 73.17M | 134.37M | |||
| Marketable Securities | 8.00K | 7.00K | 59.00K | 41.00K | N/A | |||
| Receivables | 3.04M | 5.09M | 4.33M | 5.82M | 9.68M | |||
| Inventories | N/A | N/A | 0.00 | 358.00K | 1.40M | |||
| Other Current Assets | 793.00K | 1.26M | 793.00K | 2.19M | 4.46M | |||
| Total Current Assets | 42.63M | 40.05M | 49.63M | 81.58M | 149.91M | |||
| Non-Current Assets | ||||||||
| PPE Net | 2.98M | 25.83M | 29.09M | 35.64M | 15.27M | |||
| Investments And Advances | N/A | N/A | 1.09M | 718.00K | 1.05M | |||
| Intangibles | 5.00K | 15.00K | 589.00K | 603.00K | 1.61M | |||
| Other Non-Current Assets | 195.00K | 876.00K | N/A | 1.00K | N/A | |||
| Total Non-Current Assets | 3.18M | 26.72M | 30.77M | 36.96M | 17.93M | |||
| TOTAL ASSETS | 45.81M | 66.77M | 80.40M | 118.55M | 167.84M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 1.43M | 0.00 | |||
| Current Portion Of LT Debt. | 3.34M | 1.98M | 3.87M | 99.00K | 776.00K | |||
| Accrued Expenses | 2.80M | 3.72M | 4.15M | 3.63M | 3.15M | |||
| Accounts Payable | 5.12M | 14.15M | 20.91M | 13.78M | 16.66M | |||
| Other Current Liabilities | 424.00K | 154.00K | 416.00K | 954.00K | 69.00K | |||
| Total Current Liabilities | 11.68M | 20.00M | 29.35M | 19.88M | 20.65M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 10.23M | 18.11M | 19.16M | 11.28M | 62.00K | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | 0.00 | |||
| Other Non-Current Liabilities | 419.00K | 5.80M | 5.36M | 1.83M | 1.53M | |||
| Total Non-Current Liabilities | 10.65M | 23.92M | 24.52M | 13.11M | 1.59M | |||
| TOTAL LIABILITIES | 22.32M | 43.92M | 53.86M | 32.99M | 22.24M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -29.99M | -79.09M | -97.92M | -199.27M | -137.75M | |||
| Additional Paid In Capital | 48.98M | 97.62M | 120.70M | 281.69M | 281.75M | |||
| Common Shares | 3.10M | 3.10M | 2.01M | 1.79M | 1.79M | |||
| Other Shareholders' Equity | 1.40M | 1.22M | 1.74M | 1.34M | -189.00K | |||
| Shares Outstanding | 31.02M | 31.02M | 20.06M | 17.94M | 17.94M | |||
| Tangible Book Value per Share | 0.76 | 0.74 | 1.29 | 4.74 | 8.03 | |||
| Total Shareholders' Equity | 23.49M | 22.84M | 26.54M | 85.56M | 145.60M | |||
| TOTAL LIABILITIES AND EQUITY | 45.81M | 66.77M | 80.40M | 118.55M | 167.84M | |||
| Statistics | ||||||||
| Debt/Equity | 0.44 | 0.79 | 0.72 | 0.15 | 0.00 | |||
| Current Ratio | 3.65 | 2.00 | 1.69 | 4.10 | 7.26 | |||
| Return On Assets (ROA) | -0.50% | -80.57% | -91.17% | -52.86% | -22.77% | |||
| Return On Equity (ROE) | -0.97% | -235.49% | -276.20% | -73.23% | -26.25% | |||
All data in EUR